How Percutaneous Aortic Valve Implantation is Emerging as an Alternative Treatment for Bicuspid Aortic Valve Disease?

Bicuspid aortic valve disease is a congenital heart defect that affects 1-2% of the general population. This disease was previously thought to be a relative contraindication to percutaneous aortic valve implantation (PAVI), also known as transcatheter aortic valve replacement (TAVR). Recent studies have indicated that PAVI may be a useful treatment option for people with bicuspid aortic valve disease, particularly for those who are at high surgical risk or who have comorbid conditions that make open-heart surgery more difficult.

As per a report by Research Dive, the global percutaneous aortic valve implantation market is expected to grow with a CAGR of 14.1% in the 2022-2031 timeframe. This is mainly due to the growing use of percutaneous aortic valve implantation (PAVI) in bicuspid aortic valve disease treatment.

Recent Studies show that PAVI can be an Effective Treatment Option

One study published in the Journal of the American College of Cardiology in 2019 examined the outcomes of 1,650 patients who underwent PAVI for aortic stenosis, including 101 with bicuspid aortic valves. Patients with bicuspid aortic valve disease had similar rates of procedural success, complications, and mortality as those with tricuspid valves, according to the study.

Another study published in the Journal of Thoracic and Cardiovascular Surgery in 2020 looked specifically at the outcomes of PAVI in patients with bicuspid aortic valve disease who were at high surgical risk. The researchers discovered that PAVI had a low rate of complications and mortality, and that the procedure was a viable and effective option for these patients.

Despite these encouraging findings, it is important to note that PAVI is not appropriate for all patients with bicuspid aortic valve disease. When deciding whether PAVI is the best treatment option, factors, such as valve morphology, the presence of aortic calcification, and other comorbidities should be carefully considered.

The Percutaneous Aortic Valve Implantation Market Experiences Massive Boom

The increasing use of percutaneous aortic valve implantation (PAVI) in bicuspid aortic valve disease has benefited the PAVI market in a variety of ways.

Firstly, the increased use of PAVI in bicuspid aortic valve disease has massively increased demand for PAVI procedures. The number of PAVI procedures is likely to increase as PAVI becomes a more accepted treatment option for this patient population, thus driving growth of the PAVI market.

On the other hand, the increased use of PAVI in the treatment of bicuspid aortic valve disease has created a new market segment for PAVI device manufacturers. PAVI devices were traditionally designed primarily for patients with tricuspid aortic valves, and device manufacturers had to adapt their devices to accommodate the unique anatomy of patients with bicuspid valves. This has resulted in the development of new device designs and modifications, opening up new avenues for device manufacturers to expand their product portfolios.

Moreover, the positive outcomes of PAVI in bicuspid aortic valve disease have accelerated the adoption and implementation of PAVI by physicians and healthcare providers. As more data supporting the safety and effectiveness of PAVI in patients with bicuspid valves becomes available, physicians are more likely to recommend the procedure to their patients, potentially leading to increased utilization and growth in the PAVI market.

The Bottom Line

PAVI has emerged as a feasible treatment option for patients with bicuspid aortic valve disease, particularly those at high surgical risk. More research is needed to assess the safety and efficacy of PAVI in this patient population, but these recent findings suggest that PAVI may play a growing role in the treatment of bicuspid aortic valve disease.

Overall, the increased use of PAVI in bicuspid aortic valve disease has benefited the PAVI market by opening up new market segments and increasing acceptance and adoption among physicians and healthcare providers. As PAVI technology advances and new clinical evidence becomes available, the PAVI market is projected to develop and expand in the coming years.

About the Author(s)

Princy A. J

Princy holds a bachelor’s degree in Civil Engineering from the prestigious Tamil Nadu Dr. M.G.R. University at Chennai, India. After a successful academic record, she pursued her passion for writing. A thorough professional and enthusiastic writer, she enjoys writing on various categories and advancements in the global industries. She plays an instrumental role in writing about current updates, news, blogs, and trends.